Altimmune successfully launched its global Phase 3 trial in MASH and received Breakthrough Therapy Designation from the FDA.
2 reports, 1 independent
Updated Sep 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Altimmune successfully launched its global Phase 3 trial in MASH and received Breakthrough Therapy Designation from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Novo Nordisk's Wegovy received FDA approval for treating MASH, posing a competitive challenge to Madrigal Pharmaceuticals' Rezdiffra.
- INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- Tangram Therapeutics is developing investigational treatments aimed at addressing the condition MASH (metabolic dysfunction-associated steatohepatitis).